Adjuvant chemotherapy in average-risk adult medulloblastoma patients improves survival: a long term study

Adjuvant chemotherapy in average-risk adult medulloblastoma patients improves survival: a long term study

Abstract Background Medulloblastoma is extremely rare in adults. The role of chemotherapy for average-risk adult patients remains controversial. Surgery and radiotherapy provide a significant disease control and a good prognosis, but about 25% of average-risk patients have a relapse and die because...

Full description

Bibliographic Details
Main Authors: E. Franceschi, S. Minichillo, A. Mura, A. Tosoni, M. Mascarin, C. Tomasello, S. Bartolini, A. A. Brandes
Format: Article
Language:English
Published: BMC 2020-08-01
Series:BMC Cancer
Subjects:
Medulloblastoma
Chemotherapy
Survival
Average-risk
Online Access:http://link.springer.com/article/10.1186/s12885-020-07237-x

Internet

http://link.springer.com/article/10.1186/s12885-020-07237-x

Similar Items